Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Why using current medications to select a medicare Part D plan may lead to higher out-of-pocket payments.

Domino ME, Stearns SC, Norton EC, Yeh WS.

Med Care Res Rev. 2008 Feb;65(1):114-26. Epub 2007 Oct 17.

PMID:
17942795
2.

Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

Goedken AM, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.

PMID:
20511109
3.

Should healthy Medicare beneficiaries postpone enrollment in Medicare Part D?

Atherly A, Dowd B.

Health Econ. 2009 Aug;18(8):921-31. doi: 10.1002/hec.1413.

PMID:
18972327
4.

PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.

Cline RR, Worley MM, Schondelmeyer SW, Schommer JC, Larson TA, Uden DL, Hadsall RS.

Res Social Adm Pharm. 2010 Jun;6(2):130-42. doi: 10.1016/j.sapharm.2010.04.002.

PMID:
20511112
5.
6.

The Medicare Part D doughnut hole: effect on pharmacy utilization.

Sun SX, Lee KY.

Manag Care Interface. 2007 Sep;20(9):51-5, 59.

PMID:
18161394
7.

Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.

Walberg MP, Patel RA, Amaral MM.

J Med Econ. 2008;11(4):625-37. doi: 10.3111/13696990802581079.

PMID:
19450072
8.

Cost minimization of medicare part D prescription drug plan expenditures.

Patel RA, Lipton HL, Cutler TW, Smith AR, Tsunoda SM, Stebbins MR.

Am J Manag Care. 2009 Aug;15(8):545-53.

9.
10.

Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.

Conwell LJ, Esposito D, Garavaglia S, Meadows ES, Colby M, Herrera V, Goldfarb S, Ball D, Marciniak M.

Am J Geriatr Pharmacother. 2011 Aug;9(4):241-9. doi: 10.1016/j.amjopharm.2011.04.009. Epub 2011 May 26.

PMID:
21616722
11.

Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.

Neuman P, Strollo MK, Guterman S, Rogers WH, Li A, Rodday AM, Safran DG.

Health Aff (Millwood). 2007 Sep-Oct;26(5):w630-43. Epub 2007 Aug 21.

12.

Growing differences between Medicare beneficiaries with and without drug coverage.

Poisal JA, Murray L.

Health Aff (Millwood). 2001 Mar-Apr;20(2):74-85.

13.

Out-of-pocket pharmacy expenditures for veterans under medicare part D.

Rupper RW, Bair BD, Sauer BC, Nebeker JR, Shinogle J, Samore M.

Med Care. 2007 Oct;45(10 Supl 2):S77-80.

PMID:
17909387
14.

Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.

Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):201-6. doi: 10.1016/j.drugalcdep.2010.08.016. Epub 2010 Dec 4.

PMID:
21134724
15.

Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.

Brill JV.

Am J Health Syst Pharm. 2007 Aug 1;64(15 Suppl 10):S3-6; quiz S21-S23. Review.

PMID:
17646551
16.

Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.

Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ.

J Health Care Finance. 2011 Winter;38(2):38-53.

PMID:
22372031
17.

Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.

Jung K, McBean AM, Kim JA.

J Manag Care Pharm. 2012 Mar;18(2):106-15.

18.

Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.

Thomas CP, Sussman J; Massachusettes Health Policy Forum; Massachusetts Medicaid Policy Institute.

Issue Brief (Mass Health Policy Forum). 2007 May 30;(32):1-32.

PMID:
17546802
19.

Increases in Medicare prescription drug plan costs attributable to psychotropic medications.

Zivin K, McCammon RJ, Davis MM, Halasyamani LK, Kales HC.

Am J Geriatr Psychiatry. 2008 Aug;16(8):674-85. doi: 10.1097/JGP.0b013e3181794591.

PMID:
18669946
20.

Promoting access and reducing expected out-of-pocket prescription drug costs for vulnerable Medicare beneficiaries: a pharmacist-directed model.

Cutler TW, Stebbins MR, Smith AR, Patel RA, Lipton HL.

Med Care. 2011 Apr;49(4):343-7. doi: 10.1097/MLR.0b013e318202a9f2.

PMID:
21407030

Supplemental Content

Support Center